THYROCYTES EXPRESS INFLAMMATORY MEDIATORS

甲状腺细胞表达炎症介质

• 批准号: 7376062
• 负责人: ANDREW G GIANOUKAKIS
• 金额: $ 16.22万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376062
• 关键词: THYROCYTES; EXPRESS; INFLAMMATORY; MEDIATORS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Graves' disease is a common autoimmunine disease. Patients who have this disease are hyperthyroid and can develop a throid goiter, ophthalmopathy and/or dermopathy. We believe that antibodies and other factors (IL-16) present in the serum of patients with Graves' disease are important mediators of the inflammatory process, which characterizes the tissues affected by this disease. Some patients with Graves' disease have elevated levels of the cytokine IL-16 in their blood. We propose to measure and follow for 48 months, IL-16 levels in the blood of patients with Graves' disease and attempt to correlate these levels with the clinical severity and progression (for 48 months) of Graves' disease. IL-16 levels will also be measured in normal control subjects. Antibodies will be extracted from the blood samples donated by the study patients and used in cell culture experiments with thyroid cells. These experiments will 1) investigate the pathogenesis of thyroid inflammation and 2) identify potential therapeutic targets for interrupting the processes, which lead to the development of Graves' disease.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。Graves病是一种常见的自身免疫性疾病。患有这种疾病的患者是甲状腺功能亢进，并可发展为甲状腺肿、眼病和/或皮肤病。我们认为，抗体和其他因素（IL-16）存在于Graves病患者的血清中是炎症过程的重要介质，其特征是受这种疾病影响的组织。一些格雷夫斯病患者血液中细胞因子IL-16水平升高。我们建议测量并随访48个月，Graves病患者血液中的IL-16水平，并试图将这些水平与Graves病的临床严重程度和进展（48个月）相关联。还将在正常对照受试者中测量IL-16水平。将从研究患者捐献的血液样本中提取抗体，并用于甲状腺细胞的细胞培养实验。这些实验将1）研究甲状腺炎症的发病机制，2）确定潜在的治疗靶点，以中断导致格雷夫斯病发展的过程。